Helix Biopharma Corp. (TSE:HBP) has released an update.
Helix BioPharma Corp., a clinical-stage biopharmaceutical company, has announced a delay in filing its interim financial statements, originally due on March 1, 2024. The company has requested a voluntary management cease trade order, which, if approved, will restrict its executives from trading shares but will not affect public trading. Helix reassures that there are no undisclosed material changes or information and aims to complete the filings by May 18, 2024.
For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.
